Melhores Imunoterapia médicos em Israel - TOP-22 médicos

A Dra. Pelles Sharon é especializada em imunoterapia, incluindo tratamentos como Keytruda, no Sourasky Medical Center (Ichilov).

• Experiente em vários tratamentos de câncer com foco em imunoterapia
• Contribuiu para a pesquisa clínica sobre as atitudes de pacientes oncológicos em relação a ensaios
• Realiza procedimentos avançados como Quimioterapia Intraperitoneal Hipertérmica (HIPEC)
• Oferece terapias direcionadas juntamente com tratamentos tradicionais de câncer

O Prof. Merimsky lidera a pesquisa em imunoterapia no Centro Médico Sourasky, com décadas de experiência em tratamentos avançados contra o câncer.

• Chefe da Unidade de Oncologia de Tecidos Moles e Ossos
• Membro do corpo docente do grupo Sarcoma da Sociedade Europeia de Oncologia Médica (ESMO)
• Extensas colaborações de pesquisa com o Instituto Weizmann e o Centro de Pesquisa Médica Felsenstein
• Mais de 20 anos de experiência na prática clínica de oncologia

O Dr. Sarid, oncologista sênior no Ichilov, é especializado em terapia biológica do câncer, com mais de 30 artigos publicados sobre tratamentos oncológicos.

• Mais de 15 anos como oncologista sênior no Centro Médico Sourasky
• Investigador principal em ensaios clínicos para terapias contra o câncer
• Treinamento especializado em uro-oncologia pela Universidade de Oxford
• Membro da ESMO e ASCO – organizações líderes em oncologia

Especialista em Ginecologia Oncológica e Radioterapia – O Dr. Sapra traz experiência focada em casos de imunoterapia no Sourasky Medical Center.

• Especializa-se em tratamentos de oncologia ginecológica
• Experiência em aplicações de radioterapia
• Pratica em um centro médico líder em Israel

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

O Dr. Ido Wolf lidera a Divisão de Oncologia Médica no Sourasky Medical Center, com especialização em imunoterapia.

• Chefe da Divisão de Oncologia Médica no Sourasky Medical Center
• Formação pela Universidade Ben Gurion do Neguev
• Experiência em Oncologia, Medicina Interna e Unidades Médicas Militares

Líder de ensaios de imunoterapia no Sourasky Medical Center – O Dr. Raphael é especialista em perfil genômico e injeções intratumorais para cancros torácicos.

• Investigador principal de múltiplos ensaios clínicos de imunoterapia, incluindo estudos com pembrolizumab
• Especialista em biópsias líquidas e sequenciação do reportório de células T para resposta ao tratamento
• Moderador do Conselho de Tumores Moleculares da Sociedade Israelita de Cancro do Pulmão
• Homenageado como Professor Excecional na faculdade de medicina da Universidade de Tel-Aviv
• Formação especializada (Fellowship) em Inovação e Empreendedorismo em Medicina e Health-Tech

Diretor do Serviço de Neuro-oncologia com mais de 25 anos de especialização em tumores cerebrais. O Dr. Blumenthal lidera programas de imunoterapia no Centro Médico Sourasky.

• Treinamento realizado no Memorial Sloan-Kettering Cancer Center
• Ex-diretor no Instituto do Câncer Huntsman
• Especializa-se em tratamentos avançados de neuro-oncologia

Diretor de Internamento Oncológico no Centro Médico Tel Aviv – O Dr. Stepfansky lidera a pesquisa e o tratamento de imunoterapia em Ichilov.

• Mais de 15 anos de especialização em oncologia
• Pesquisador principal em ensaios clínicos de fase 1 a 3
• Treinamento realizado no Centro Médico Tel Aviv
• Especialista em medicina interna e oncologia

O Dr. Dror Levin é um especialista líder em hemato-oncologia pediátrica, especializado no tratamento do câncer ósseo (sarcoma) para crianças no Centro Médico Sourasky em Tel Aviv.

• Diretor do departamento de hemato-oncologia infantil no Centro Médico Sourasky
• Especializou-se em hematologia e oncologia pediátrica no Centro Médico Infantil Schneider
• Membro da associação israelense de hemato-oncologia pediátrica (ISPHO)
• Treinamento em oncologia de ossos e tecidos moles no Instituto Ortopédico Rizzoli na Itália

O Dr. Fredi Aviv traz 31 anos de experiência especializada em onco-hematologia no Sourasky Medical Center (Clínica Ichilov).

• Especialista em tratamentos de imunoterapia para cânceres do sangue
• Vasta experiência com malignidades hematológicas complexas
• Atua em um dos principais centros médicos de Israel

O Dr. Amir é especializado em terapia direcionada com Keytruda (Pembolizumab) para câncer de mama, com mais de 30 apresentações em reuniões científicas.

• Ganhador de múltiplos prêmios, incluindo o Prêmio ESMO de Pesquisa Translacional em Câncer de Mama
• Membro da Sociedade Europeia de Oncologia Clínica (ESMO)
• Bolsa de Pesquisa em Câncer de Mama na Emory University
• Mais de 15 anos de experiência em oncologia

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Médico Chefe do Centro de Oncologia do Assuta Medical Center, o Dr. Tepper é especialista em tratamentos de imunoterapia.

• Anos de experiência em oncologia com foco em terapias inovadoras
• Lidera equipas dedicadas para planos de tratamento personalizados
• Envolvido ativamente no avanço dos protocolos de imunoterapia

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.